VTE Prevention Following Total Hip and Knee Arthroplasty

Phase 3 Completed 5429 enrolled Sudeep Shivakumar Canadian Institutes of Health Research (CIHR) · collab Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network · collab Nova Scotia Health Authority · collab

RandomizedSequentialQuadruple-blindPrevention

Summary

Consented patients undergoing elective total hip and total knee arthroplasty will be randomized to receive either aspirin alone or aspirin and rivaroxaban for prevention of venous thromboembolism.

Timeline

Start: 2021-02-04
Primary completion: 2025-04-16
Completion: 2026-06-10

Publications

Shivakumar S, Matino D, Zukor D, Kahn SR, Vincent G, Mundi R, Vendittoli PA, Refaei M, Bohm E, Tanzer M, Pelet S, Richardson G, Powell J, Ikesaka R, Douketis J, Ward S, Kim P, Mann S, Pleasance S, Cormier J, Andreou P, Matheson K, Theriault C, West C, Anderson D, Gross PL; EPCAT III Trial Investigators. Rivaroxaban Then Aspirin vs. Aspirin Alone after Total Hip or Knee Arthroplasty. N Engl J Med. 2026 Jul 12. doi: 10.1056/NEJMoa2603649. Online ahead of print.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Aspirin	Small molecule	81 mg	—
Comparator	Rivaroxaban	Other / unclassified	10 mg	Oral

VTE Prevention Following Total Hip and Knee Arthroplasty

Summary

Timeline

Publications

Drugs

Indications